Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

• Published in: British journal of clinical pharmacology 1998-04, Vol.45 (4), p.412-415
• Main Authors: Brefel, C., Thalamas, C., Rayet, S., Lopez‐Gil, A., Fitzpatrick, K., Bullman, S., Citerone, D. R., Taylor, A. C., Montastruc, J. L., Rascol, O.
• Format: Article
• Language: English
• Subjects: Aged; Anticonvulsants. Antiepileptics. Antiparkinson agents; Antiparkinson Agents - adverse effects; Antiparkinson Agents - pharmacokinetics; Antiparkinson Agents - therapeutic use; Area Under Curve; Biological and medical sciences; dopaminergic agonist; Female; food interaction; Food-Drug Interactions; Half-Life; Humans; Indoles - adverse effects; Indoles - pharmacokinetics; Indoles - therapeutic use; Male; Medical sciences; Middle Aged; Neuropharmacology; Original; Parkinson Disease - drug therapy; Parkinson Disease - metabolism; Parkinson’s disease; pharmacokinetics; Pharmacology. Drug treatments; ropinirole
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1046/j.1365-2125.1998.t01-1-00704.x

Aims  Ropinirole is a specific non‐ergoline dopamine D2‐receptor agonist with antiparkinsonian properties.The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co‐administered with food. Methods  This was an open, randomized, two sessions cross over study in 12 patients with Parkinson’s disease, comparing the steady‐state pharmacokinetic profiles of ropinirole on two different study days: ‘fasted’ and ‘fed’. Results  The mean Cmax was lower in the ‘fed’ regimen than in the ‘fasted’ one (−25%, P=0.002). The median tmax was observed 2.6 h later in the ‘fed’ regimen than in the ‘fasted’ regimen (P